Clinical Efficacy
MCC1274: Memory Bifidobacterium
MCC1274 improves cognitive function in people with mild cognitive impairment
In a preliminary study, elderly subjects with a high possibility of mild cognitive impairment (MCI) were asked to take Bifidobacterium breve MCC1274 (20 billion CFU/day), and changes were verified by a cognitive function evaluation test (Mini-Mental State Exam: MMSE). As a result, a significant increase in cognitive function was observed after 16 and 24 weeks of intake.
An RCT study confirmed that MCC1274 helps to maintain memory, a part of cognitive function
Furthermore, we tested changes in cognitive function assessed by RBANS in elderly who were concerned about forgetfulnesssubjects (age: 50-79 years old, subject number: MCC1274 group = 40, Placebo group = 40), after having them take Bifidobacterium breve MCC1274 (20 billion CFU/day). The results showed that the subjects who took Bifidobacterium breve MCC1274 showed significant improvement in immediate memory score, delayed memory score and visuospatial/constructional score in RBANS compared to the placebo group.